close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.9200 -0.0400 (-4.17%)
Delayed Quote Updated: 9:56 AM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ocugen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Ocugen Q3 Earnings Call Highlights ↗
Ocugen (NASDAQ:OCGN) said its third-quarter progress centered on advancing three retinal gene therapy programs in late-stage development, expanding regional partnerships and establishing a European... 
Via MarketBeat
Topics Earnings
News headline image
Ocugen (OCGN) Q3 2026 Earnings Call Transcript ↗
Management outlined three Phase III readouts and a new Middle East licensing deal. 
Via The Motley Fool
Topics Earnings
News headline image
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances ↗
Ocugen (NASDAQ:OCGN) is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive... 
Via MarketBeat
Ocugen (NASDAQ:OCGN) Falls on Mixed Q2 Results as Revenue Beat Offsets Wider Loss ↗
Via Chartmill
Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028 ↗
Via Chartmill
Ocugen Inc (NASDAQ:OCGN) Stock Drops 7% on Q4 Revenue Miss, Highlights Clinical Pipeline ↗
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Demystifying Ocugen: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts ↗
Ocugen (NASDAQ:OCGN) is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in... 
Via MarketBeat
News headline image
Ocugen (OCGN) Q2 2026 Earnings Call Transcript ↗
Gene therapy developer advances three Phase III programs toward 2028 regulatory filings. 
Via The Motley Fool
Topics Earnings Retirement
News headline image
Ocugen Q2 Earnings Call Highlights ↗
Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT... 
Via MarketBeat
Topics Earnings
News headline image
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances ↗
Ocugen (NASDAQ:OCGN) outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying the company is targeting biologics license applications for retinitis... 
Via MarketBeat
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Investors can find much better opportunities. 
Via The Motley Fool
Top movers in Monday's after hours session ↗
Via Chartmill
News headline image
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data ↗
Canaccord has a $12 price target on the stock, representing a potential upside of about 415% from the stock’s closing price on Monday. 
Via Stocktwits
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
Ocugen (OCGN) Q4 2025 Earnings Call Transcript ↗
Ocugen (OCGN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Why Did OCGN Stock Rise Today? ↗
Ocugen said that it intends to start seeking the approval of the FDA for its experimental therapy OCU400 starting this year. 
Via Stocktwits
News headline image
Ocugen Stock Is Surging Today: What&#39;s Driving The Action? ↗
Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment. 
Via Benzinga
News headline image
OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder ↗
Stargardt disease is a form of inherited macular degeneration, affecting more than 100,000 people in the U.S. and Europe combined. 
Via Stocktwits
News headline image
Ocugen (OCGN) Q3 2025 Earnings Call Transcript ↗
Ocugen (OCGN) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
OCUGEN INC (NASDAQ:OCGN) Reports Mixed Q3 2025 Results Amid Clinical Pipeline Progress ↗
Ocugen reports Q3 2025 results with a major revenue beat and updates on its late-stage gene therapy pipeline for blindness diseases. 
Via Chartmill
News headline image
Forecasting The Future: 4 Analyst Projections For Ocugen ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Ocugen Stock Zoomed 12% Higher Today ↗
A peer across the Pacific Ocean has purchased the rights to one of the biotech's pipeline drugs. 
Via The Motley Fool
News headline image
Ocugen Shares Are Trading Higher Monday: What's Going On? ↗
Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400. 
Via Benzinga
News headline image
Ocugen (OCGN) Q2 Revenue Jumps 20% ↗
Via The Motley Fool
News headline image
Ocugen Inc (NASDAQ:OCGN) Q2 2025 Earnings: Revenue Surges, EPS Loss Narrows ↗
Ocugen Inc (OCGN) reports Q2 2025 earnings with $1.37M revenue, beating estimates by 284%, while EPS loss narrows to -$0.05. Progress in gene therapy trials boosts investor optimism. 
Via Chartmill
News headline image
Earnings Scheduled For August 1, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.